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Neuropathic pain arises as a direct consequence of a lesion or disease affecting the peripheral somatosensory system. It may be
associatedwith allodynia and increased pain sensitivity. Few studies correlated neuropathic painwith nervemorphology andmyelin
proteins expression. Our aimwas to test if neuropathic pain is related to nerve degeneration, speculating whether themodulation of
peripheral GABA-B receptors may promote nerve regeneration and decrease neuropathic pain.We used the partial sciatic ligation-
(PSL-) induced neuropathic model. The biochemical, morphological, and behavioural outcomes of sciatic nerve were analysed
following GABA-B ligands treatments. Simultaneous 7-days coadministration of baclofen (10mg/kg) and CGP56433 (3mg/kg)
alters tactile hypersensitivity. Concomitantly, specific changes of peripheral nervemorphology, nerve structure, andmyelin proteins
(P0 and PMP22) expression were observed. Nerve macrophage recruitment decreased and step coordination was improved. The
PSL-induced changes in nociception correlate with altered nerve morphology and myelin protein expression. Peripheral synergic
effects, via GABA-B receptor activation, promote nerve regeneration and likely ameliorate neuropathic pain.
1. Introduction
Neuropathic pain is primed by lesions to the somatosensory
nervous system. It is characterized by a reduced nociceptive
threshold and sometimes by spontaneous pain in the absence
of stimuli, so that normally innocuous stimuli can produce
pain. As a consequence, neuropathic pain may be partially
associated with a state of tactile hypersensitivity (allodynia)
and hyperalgesia [1]. These altered sensory features may be
reproduced in rodent experimental models by a unilateral
partial injury of the sciatic nerve.The “partial sciatic ligation”
(PSL) shows many of the typical symptoms of the complex
regional pain syndrome- (CRPS-) II, a human chronic pain
condition associated with nerve injuries, including the rapid
onset of allodynia [2]. In rodents, the behavioural hyper-
sensitivity can be measured as a reduction in the thresh-
old of sensory stimulation required for limb withdrawal
behaviour. However, very few studies correlated the PSL-
induced neuropathic pain with nerve morphology. Recently,
studies performed with the PSL model have proposed new
drug candidates and therapeutic targets to reduce neuro-
pathic pain [3–7]. However, current pharmacotherapies for
neuropathic pain are still unsatisfactory.
Although the involvement of the somatosensory system is
associated with a wide range of neuropathic pain conditions,
ranging from peripheral neuropathy to central post-stroke
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pain, neuropathic pain may be the consequence of a painful
peripheral nerve injury [8]. In the last decade, given the
increasing knowledge of the mechanisms regulating degen-
eration/regeneration of peripheral nerves several approaches
to promote nerve regeneration have been addressed. The
administration of neurotrophins [9–11], extracellular matrix
molecules [12, 13], and cyclic adenosine monophosphate
(cAMP) modulators [14] or the application of electrical
stimulation [15, 16] has been proposed. Unfortunately, none
of these methods was introduced in clinic, and currently
available therapies are mainly addressed to the control of
painful symptoms rather than to treat nerve degeneration
and/or to promote regeneration. New strategies that simulta-
neously control nerve regeneration and neuropathic pain are
needed.
The first working hypothesis that we tried to validate was
to assess whether the PSL induces changes (e.g., in allodynia)
that may correlate with alterations in nerve morphology
and/or in myelin proteins expression.
The gamma-aminobutyric acid (GABA) signalling sys-
tem has been proposed as a target of possible therapies
addressed to promote the recovery from neuropathic pain
[17–19]. GABA-B receptors are present in the neuronal
compartment of the spinal cord white matter [20, 21] and
are highly expressed in the laminae I–IV of the dorsal horn
[22–25]. At these sites, GABA-B receptors colocalize with
glutamic acid decarboxylase (GAD) enzyme and primary
afferent fibers [23, 26, 27]. GABA-B receptor isoforms were
also found in the rat dorsal root ganglia (DRG), in peripheral
axons, in autonomic nerve terminals, and in pig nodose
ganglion cells [22, 28–32]. Mice lacking functional GABA-
B receptors exhibit pronounced hyperalgesia in a number
of acute pain tests, corroborating the hypothesis of a role
for GABA-B receptors in nociception [33, 34]. Very recently,
Schwann cells were shown to express different isoforms of
GABA-B receptor, such as −1a, −1b, and −2, which can
participate in the control of the Schwann cell development
and in the myelination process [35, 36]. The peripheral
GABA-B receptors in Schwann cells may be involved in the
regulation of the sensory and nociceptive functions [37, 38].
A number of clinical studies suggested that GABA-B
agonists might be useful for the treatment of neuropathic
pain. For example, the GABA-B agonist baclofen showed
antinociceptive effects in the postherpetic neuralgia, in
diabetic neuropathy, and in migraine [39–42]. Following
systemic, supraspinal, and spinal administration, baclofen
proved antinociceptive in animalmodels of chronic pain [43–
47].
Therefore, we hypothesized that the modulation of the
peripheral GABA-B receptors in nerves may contribute to
ameliorate neuropathic pain via promotion of nerve regen-
eration. To test this working hypothesis, here we evalu-
ated the putative therapeutic effects of two GABA-B lig-
ands (the agonist baclofen and the antagonist CGP56433)
on some behavioural, biochemical, and morphological
parameters of peripheral nerves. The rationale to use
either a GABA-B agonist or an antagonist was to test
whether the GABA-B-mediated action in the PNS may
be the consequence of a receptor stimulation or inhibi-
tion.
2. Materials and Methods
2.1. Animals and Surgery. In this studymale Sprague-Dawley
rats were used (Charles River, Calco, Italy). All the animals
were anesthetized by an intraperitoneal (i.p.) injection of
a mixed solution of ketamine (80mg/Kg) and xylazine
(5mg/Kg).The experimentalmodel of PSL has been achieved
following the method of Seltzer et al. [2]. Briefly, an incision
was made through skin and muscle of the right hind limb.
Thenervewas then exposed and, for the experimental groups,
ligated with a node made using a suture (Vicryl 3-0 2),
which crossed the nerve at half or 1/3 of its diameter. The
lesion was done 1 cm proximally to the forking of the sciatic
nerve into the peroneal and tibial branches. Seven days after
surgery, animals were terminated by anesthetic overdose and
the nerves collected at −80∘C. All the experiments were
performed according to the Animal Research Committee
of our Institution and in compliance with the policy on
the use of animals approved by the European Community
Council Directive (2010/63/EC). Our study was approved by
the Animal Care and Use Committee.
2.2. Pharmacological Treatments. In each experiment, 4 rats
were used as sham operated animals (control group), while
16 rats underwent PSL. The PSL rats were then divided
into 4 experimental groups for treatments: (1) PSL + vehicle
(saline solution); (2) PSL + baclofen (10mg/kg); (3) PSL +
CGP56433 (3mg/kg); (4) PSL + baclofen + CGP56433. The
pharmacological treatments started the day of PSL surgery
(day 0) and lasted 7 days, consisting in the administration
of i.p. injection twice a day. Experiments were done at
least 3 times. All GABA-B compounds were provided by K.
Kaupmann, Novartis Pharma AG, Basel, Switzerland.
2.3. Mechanical Allodynia and Thermal Hyperalgesia. Ani-
mals were accustomed to test cages before behavioural
tests. Responses to mechanical and thermal stimuli were
performed on the ipsilateral hind paws of sham and PSL rats
at different time points (i.e., 1 day and 7 days postsurgery).
Mechanical allodynia was assessed using the dynamic plantar
aesthesiometer (Ugo Basile, Comerio, Italy). Rats were placed
in the test cage with a wire mesh floor and a rigid tip of a Von
Frey-filament (punctate stimulus) was applied in the middle
of the skin of the hind paw.Thefilament exerted an increasing
force, up to 45 g in 35 sec. We measured the withdrawal
threshold, expressed in grams (g), until each animal removed
its paw. Thermal hypersensitivity was tested according to
the Hargreaves procedure [48] using the Basile plantar test
apparatus (Ugo Basile). A constant intensity radiant heat
source (beam diameter 0.5 cm and intensity 40 I.R.) was
aimed at the midplantar area of the hind paw. We recorded
[in seconds (s)] the time interval (named as latency) from the
heat source activation, until each animal withdrew its paw.
The thresholds were measured repeatedly, to each time point
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(1 day and 7 days postsurgery), and the values are the mean
of 4 evaluations of each animal ± SEM.
2.4. RNAse Protection Assay (RPA). Total RNA was isolated
from sciatic nerves by phenol-chloroform extraction and 5𝜇g
of each sample were processed as described [49]. Briefly, the
samples were dissolved in 20𝜇L of hybridization solution
containing [32P]-labeled cRNA probes, 250,000 counts per
minute (CPM) for glycoprotein P0 (P0) and peripheral
myelin protein of 22 kDa (PMP22) and 50,000 CPM for
18S, and incubated at 45∘C overnight. The following day,
the samples were incubated 30min at 30∘C with 200𝜇L of
digestion buffer containing 1 𝜇g/𝜇L RNase A and 20U/𝜇L
RNase T1 (Sigma-Aldrich, Milan, Italy) then treated for
15min at 37∘Cwith 10 𝜇g of proteinase K and sodium dodecyl
sulfate (SDS) 20%. After phenol-chloroform extraction, the
samples were separated on a 5% polyacrylamide gel, under
denaturing conditions (7mol/L urea). The protected frag-
ments were visualized by autoradiography. The levels of P0
and PMP22 and 18S rRNA were calculated by measuring the
peak densitometric area with Image J software (NIH, USA)
anddatawere normalized versus 18S rRNA. In order to ensure
that the autoradiographic bands were in the linear range
of intensity, different exposure times were used. The mean
values of the controls from different experiments were within
10% of each other.
2.5. Light Microscopy (LM) and Morphological Analysis. Rats
were perfused transcardially, under deep anesthesia, with
a solution containing 2% PFA and 2% glutaraldehyde in
0.1M sodium cacodylate buffer (Sigma-Aldrich) pH 7.3.
After fixation sciatic nerves were removed and immersed in
the same fixative solution overnight at 4∘C. The specimens
were then postfixed in 2% OsO
4
(Sigma-Aldrich), dehy-
drated, and embedded in Epon-Araldite (Sigma-Aldrich).
Semithin (0.5 𝜇m) transverse sections were stained with
toluidine blue and analyzed with a Axioskop200 microscope
(Zeiss, Gottingen, Germany), at final 1500x magnification.
To assess morphological alterations of peripheral nervous
system (PNS), qualitative and quantitative analyses were
performed. Usually, 5 sections for each animal nerve were
analysed. At least 25 fields for each section, corresponding to
25%of the total nerve area, were acquired [50].Thenumber of
myelinated fibers was counted, normalized per field (in 𝜇m2),
and expressed as mean ± SEM of data.
2.6. Electron Microscopy (EM). Ultra-thin sections (60–
90 nm) for ultrastructural observations were obtained from
each sciatic nerve used for the lightmicroscopy. Sectionswere
collected on formvar film coated grids with a single hole,
counterstained with lead citrate, and examined with a Zeiss
EM10 electron microscope.
2.7. Immunofluorescence and Confocal Laser Scanning Micros-
copy (CLSM). Sciatic nerves were fixed in 4% PFA in phos-
phate buffered saline (PBS; Sigma-Aldrich) and 10 𝜇m trans-
verse frozen sections were cut. Nerve sections were incubated
30min at room temperature in presence of FluoromyelinTM
red fluorescent myelin stain (1 : 200, Life Technologies Italia,
Monza, Italy). Slides were then incubated overnight at 4∘C
in PBS 0.25% bovine serum albumin (Sigma Aldrich), 0.1%
Triton X-100, and themousemonoclonal anti-CD68 primary
antibody (1 : 200 AbCam, Cambridge, UK). The following
day slides were washed two times and incubated 2 h with
the specific goat anti-mouse FITC-antibody (1 : 200; Sigma-
Aldrich). After washing, nuclei were stained with 4󸀠,6-
diamidino-2-phenylindole (DAPI) and slides were mounted
using Vectashield𝑇𝑀 (Vector Laboratories, Burlingame, CA,
USA). Controls for specificity included a lack of primary
antibody. Confocal microscopy was carried out using a
Zeiss LSM 510 microscope and Image Pro-Plus 6.0 software
(MediaCybernetics, Bethesda, MA, USA).
2.8. Walking Test. The walking footprint test was done on all
rats of each experimental group, at the end of pharmacolog-
ical treatments. Rats with their hind feet stained with black
ink were placed on a 100 cm long gangway, which yielded at
least 10 footprints per rat. Rats did not undergo any training
before the test. Footprints were acquired and analysed with
the Footprint 1.22 program [51]. We measured the image area
touched by a single step (in cm2), the toe 1–5 and 2–4 spreads
(in cm), the length of the foot step (in cm), the stride width
and the stride length (in cm). Data of each parameter are
mean of 8–10 footprints of each animal ± SEM.
2.9. Data Analysis and Statistics. Data were statistically eval-
uated by using GraphPad Prism 4.0 software (San Diego,
USA) and Systat 12 software (Systat Inc., Chicago, USA).
Significance was determined by one-way Anova analysis
for multiple comparison using Tukey’s post hoc test for
morphometric, gait, and myelin proteins expression analysis
and by two-way Anova analysis using Bonferroni’s post hoc
test for the analysis of nociception. Quantitative data include
95% confidence intervals. 𝑃 values < 0.05 were considered
significant.
3. Results
3.1. Assessment of the PSL Experimental Model. The right
sciatic nerve was exposed and then tightened with a suture
which crossed the nerve approximately at 1/3 of its diameter
(Figure 1(a)). No signs of massive inflammatory reaction or
serum infiltrate were found (data not shown). Although
PSL has been extensively studied as a behavioural model
of neuropathic pain, few proofs of its capability to induce
morphological changes are available.The nerve degeneration
was analysed 7 days after ligation, a time point presenting
the typical signs of axonal atrophy and myelin degradation
(Figure 1(c)). The sham operated animals (controls) pre-
sented normal nerve morphology (Figure 1(b)). Considering
that the PSL-induced denervation is equal for axons of all
sizes [52], we counted the number of myelinated fibers per
field as an indirect index of nerve integrity (Table 1). They
resulted normal in sham operated rats (18.04 ± 1.12 fibers;
95% CI: 15.81–20.26), while were significantly decreased in
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Figure 1: PSL experimental model induces neurodegeneration of peripheral nerves. (a) Image of the partial ligation of the right sciatic nerve.
(b) Toluidine blue stained semithin cross-section of sham sciatic nerve in which normal myelinated fibers are appreciable. (c) Toluidine blue
stained semithin cross-section of a ligated sciatic nerve showing signs of massive neurodegeneration. Scale bar 20𝜇m.
PSL rats (2.52 ± 0.12 fibers; 95% CI: 2.28–2.76; 𝑃 = 0.000017
versus sham operated).
3.2. In PSL Rats the Mechanical Allodynia Is Counteracted by
GABA-B Ligands. We expected PSL to induce allodynia and
hyperalgesia in the injured rats. To confirm this hypothesis
we evaluated the nociceptive responses to mechanical and
thermal stimuli, after PSL and in the presence of GABA-
B ligands. As shown in Figure 2(a), the paw withdrawal
threshold (PWT) of PSL rats to mechanical stimuli decreased
significantly 1 day after nerve injury (diff. −13.56 versus sham
operated; 95%CI: −23.49/−3.63; 𝑃 = 0.000099) and lightly
increased at 7 days (diff. −5.57 versus sham operated; 95%CI:
−17.76/6.61; 𝑃 = 0.187689), despite being still lower of the
sham operated animals at 7 days postinjury. This indicates
an allodynic state. The cotreatment for 7 days with baclofen
(10mg/kg) plus CGP56433 (3mg/kg) caused a significant
recovery of the response to mechanical stimuli to the levels
observed in the sham animals (diff. −3.77 versus sham
operated; 95%CI: −14.46/6.91; 𝑃 = 0.308831), suggesting
that the cotreatment counteracts allodynia. At 7 days, neither
baclofen nor CGP56433 alone proved able to induce any
recovery to the levels of sham animals. Then, the latency
to paw withdrawal (in sec) to acute thermal stimuli was
assessed. As shown in Figure 2(b), at 7 days postinjury the
paw withdrawal was lower in PSL rats in comparison to
the sham operated rats (diff. −5.66 versus sham; 95% CI:
−16.12/4.81; 𝑃 = 0.119657). This suggests a hyperalgesic
state. As for the mechanical allodynia, the treatment with
baclofen plus CGP56433 was effective. Indeed, it induced a
significant hypoalgesia 1 day postsurgery (diff. 13.86 versus
sham; 95%CI: 2.76/24.96; 𝑃 = 0.000361) and tended to
recover the levels of sham operated animals at 7 days (diff.
−3.15 versus sham; 95% CI: −15.29/9.01; 𝑃 = 0.455421).
Also CGP56433 alone revealed a similar significant response
to a nociceptive thermal stimuli at 1 day (diff. 11.70 versus
sham operated; 95%CI: 1.87/21.54; 𝑃 = 0.000675), but at
7 days it showed a slighter recovery, tending to the levels
of sham animals (diff. −4.91 versus sham operated; 95%CI:
−15.02/5.22; 𝑃 = 0.163287).
3.3. GABA-B Ligands Improve the Peripheral Nerve Morphol-
ogy. To test the hypothesis whether the nociceptive responses
may correlate with morphological changes, the structure of
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Figure 2: Assessment of allodynia and hyperalgesia after GABA-B ligands treatment. (a) Histograms of the pawwithdrawal threshold (PWT)
of rats to innocuous stimulationwith a filament, at 1 and 7 days postsurgery. Data are expressed as percentage versus controls (sham operated).
(b) Histograms of thermal nociception of rats with a filament, at 1 and 7 days postsurgery. Latencies to paw withdrawal (in sec) were assessed
at infrared intensity 20, and data are expressed as percentage versus controls (sham operated). Statistic with two-way Anova and Bonferroni’s
post hoc test. ∗∗∗
𝑃
< 0.001, ∗∗∗∗
𝑃
< 0.0001.
Table 1: Stereologic evaluation of number of myelinated fibers in peripheral nerves of sham, PSL, and PSL-treated rats.
Number of myelinated fibers per field
Sham 18.04 ±1.12
PSL 2.52 ±0.12 𝑃 < 0.0001 versus sham
PSL + Baclofen 3.63 ±0.23
PSL + CGP56433 7.31 ±0.36 𝑃 < 0.0001 versus PSL
PSL + Baclofen + CGP56433 12.02 ±0.71 𝑃 < 0.0001 versus PSL
Statistic with one-way Anova and Tuckey’s post hoc test.
degenerated PSL nerves was analysed by light microscopy.
At least 5 semithin transverse sections (0.5𝜇m) of each
animal were examined along the degenerated/regenerated
nerves, covering all the distance from the upper to the
lower parts of the suture crossing the nerve. As shown
in Figure 3(c), the 7-day treatment with baclofen (10mg/kg
i.p.) did not change the structure, which resembled that of
PSL rats, with degenerated nerve fibers and some infiltrated
macrophages (Figure 3(b)). Nonetheless the CGP56433 treat-
ment (3mg/kg, i.p.) produced a full amelioration of the
nerve structure (Figure 3(d)). Similarly the administration of
baclofen (10mg/kg) plus CGP56433 (3mg/kg) improved the
nerve morphology (Figure 3(e)), which qualitatively resem-
bles that of sham operated rats (Figure 3(a)). To validate
these qualitative observations, we quantified the number of
myelinated fibers, as an index of nerve integrity, at 7 days
posttreatment (Table 1). As shown in Table 1 and Figure 3(f),
sham operated rats showed normal number of myelinated
fibers (18.04 ± 1.12; 95%CI: 15.81–20.26) per field, while the
PSL rats showed a significant reduction (2.52 ± 0.12; 95%CI:
2.28–2.76; 𝑃 = 0.000017 versus sham operated). However,
the number of myelinated fibers progressively increased,
depending on the treatment. Indeed, baclofen did not pro-
duce any significant increase (3.63 ± 0.23; 95%CI: 3.18–4.07;
𝑃 = 0.438372 versus PSL), while CGP56433 significantly
raised the number of myelinated fibers (7.31 ± 0.36; 95%CI:
6.61–8.01; 𝑃 = 0.000017 versus PSL). However only the
simultaneous treatment with baclofen and CGP56433 was
able to determine a significant recovery of the myelinated
fibers to sham operated levels (12.02 ± 0.71; 95%CI: 10.62–
13.43; 𝑃 = 0.000017 versus PSL).
The recovery of a normal anatomical structure of the
nerve after baclofen plus CGP56433 treatment was con-
firmed also by the EM analysis. Indeed, we observed nor-
mal myelin laminae and Schwann cells, with several small
fibers, thinly myelinated indicative of starting of nerve
regeneration (Figure 4).
3.4.TheMyelin Proteins Are Changed by the GABA-B Ligands.
To assess whether the morphologic changes may be due
to a direct effect on the myelinating Schwann cells, we
then analysed the expression of the most important myelin
proteins, P0 and PMP22. P0 is a glycoprotein accounting
for over half of the total proteins in PNS myelin, while
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Figure 3: Morphological alterations of peripheral nerves are recovered after GABA-B ligands treatment. Toluidine blue stained semithin
cross-sections of (a) sham operated rat. Evidence of normal structure of the nerve. (b) PSL rat in which a loss of myelinated fibers is evident.
The nerve fiber structure appears degenerated and macrophages (indicated by arrowheads) are observed. (c) PSL rat treated with baclofen
10mg/kg. Nerve appears still degenerated with a significant loss ofmyelinated fibers. (d) PSL rat treated with CGP56433 3mg/kg. Nerve shows
normal myelinated fibers, although some areas still contain degenerated axons (arrows). (e) PSL rat treated with baclofen + CGP56433. Nerve
shows a regeneration patternwith several normalmyelinated fibers and very few degenerated axons (arrows). Scale bar 20 𝜇m. (f)Quantitative
morphometric analysis of the number of myelinated fibers. All data are expressed asmeans ± SEM. Statistic with one-way Anova and Tuckey’s
post hoc test. ∗∗∗∗
𝑃
< 0.0001.
PMP22 represents 2–5% of the total amount of the peripheral
myelin proteins [53]. They are essential constituents required
for stabilizing compact myelin, in fact their quantitative
changes may alter Schwann cell development, growth, and
differentiation [54]. For instance, a gene deletion or a gain of
function of these proteins can cause congenital neuropathies
such as the Charcot-Marie-Tooth (CMT) disease [54]. As
shown in Figures 5(a) and 5(b) the gene expression of P0
(0.34 ± 0.08; 95%CI: 0.14–0.53; 𝑃 = 0.000137 versus sham
operated) and PMP22 (0.14 ± 0.02; 95%CI: 0.08–0.19; 𝑃 =
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Table 2: Footprint analysis of most important parameters of locomotor activity in sham, PSL, and PSL-treated rats.
Distance
1–5 toe
Distance
2–4 toe
Length
foot step
Stride
width
Stride
length
Area
touched
Sham 1.95 ±0.03 1.06 ±0.03 3.21 ±0.09 3.64 ±0.06 11.46 ±0.49 1.79 ±0.08
PSL
0.76 ±0.04 0.50 ±0.03 4.39 ±0.13 4.59 ±0.11 13.32 ±0.54 1.90 ±0.17
𝑃 =
0.000116
𝑃 =
0.000131
𝑃 =
0.000116
𝑃 =
0.000119
𝑃 =
0.404063
𝑃 =
0.968606
PSL +
baclofen
0.70 ±0.05 0.35 ±0.03 4.10 ±0.18 3.85 ±0.15 9.60 ±0.71 1.06 ±0.14
𝑃 =
0.921960
𝑃 =
0.547398
𝑃 =
0.648819
𝑃 =
0.002619
𝑃 =
0.018476
𝑃 =
0.000914
PSL +
CGP56433
1.42 ±0.05 0.86 ±0.03 2.61 ±0.12 3.28 ±0.11 9.29 ±0.64 1.13 ±0.20
𝑃 =
0.000116
𝑃 =
0.000135
𝑃 =
0.000113
𝑃 =
0.000117
𝑃 =
0.018430
𝑃 =
0.005125
PSL +
baclofen +
CGP56433
1.58 ±0.09 0.98 ±0.04 3.51 ±0.12 3.63 ±0.15 10.16 ±0.93 1.51 ±0.11
𝑃 =
0.000116
𝑃 =
0.000131
𝑃 =
0.000466
𝑃 =
0.000129
𝑃 =
0.056044
𝑃 =
0.289398
Data are expressed as mean (in cm) ± SEM. Statistic with one-way Anova and Tuckey’s post hoc test. Significance for PSL was calculated versus sham-operated,
while significance for baclofen, CGP56433, and baclofen/CGP56433 groups was calculated versus PSL.
Figure 4: Electronmicrograph picture of ultra-thin cross-section of
PSL sciatic nerve after treatmentwith baclofen+CGP56433.Normal
myelinated large fibers and small thinly myelinated regenerating
fibers are shown. Scale bar 10𝜇m.
0.000128 versus sham operated) was significantly decreased
in PSL rats. The 7-day treatment with CGP56433 (3mg/kg)
significantly restored the P0 (1.43 ± 0.27; 95% CI: 0.73–2.13;
𝑃 = 0.000146 versus PSL) and PMP22 (1.44 ± 0.14; 95%CI:
1.07–1.80; 𝑃 = 0.000128 versus PSL) mRNAs to the levels of
sham operated animals. Baclofen (10mg/kg) alone did not
change the gene expression levels of both P0 and PMP22
proteins. Surprisingly, as shown in Figures 5(a) and 5(b),
baclofen plus CGP56433 showed a partial but significant
increase in the mRNA levels of both myelin proteins: P0
(0.86 ± 0.01; 95%CI: 0.85–0.87; 𝑃 = 0.028372 versus PSL)
and PMP22 (0.53 ± 0.06; 95%CI: 0.38–0.68; 𝑃 = 0.008942
versus PSL).
3.5. Functional Assessment of the Nerve Regeneration Induced
by the GABA-B Ligands. The functional recovery of nerves
in PSL rats was then assessed by evaluating the motor
coordination and synchrony with the gait analysis. The rats
were allowed to walk in a standard corridor, leaving a trail
of footprints, which were analysed measuring the following
parameters: stride length and width, step length and area,
distance between 1–5 and 2–4 toes. In the PSL rats at 7-
day postsurgery most of the parameters were significantly
altered, if compared to the sham operated animals (see data
in Table 2). These results confirmed that the PSL injury
induces a functional motor deficit. Baclofen alone did not
show significant improvements in toes distances 1–5 and 2–
4 and in length of foot step, versus PSL (see data in Table 2).
Furthermore, baclofen worsened some parameters (Table 2),
for instance, the distances of toes 2–4, that was significantly
decreased in PSL treated with baclofen (0.35 ± 0.03; 95%CI:
0.29–0.41; 𝑃 = 0.000131 versus sham). However other
parameters, such as stride width, length, and foot step area,
were significantly increased after baclofen treatment (see data
in Table 2). The pharmacological treatment with CGP56433
or cotreatment baclofen plus CGP56433 reversed almost all
the parameters affected by PSL (Table 2). The CGP56433
treatment significantly increased the 1–5 (1.42±0.05; 95%CI:
1.32–1.51; 𝑃 = 0.00116 versus PSL) and 2–4 (1.58 ± 0.08;
95%CI: 1.40–1.76; 𝑃 = 0.000135 versus PSL) toes distances,
to the levels comparable to sham operated rats (Figure 6).The
most effective treatment was baclofen plus CGP56433 that
significantly recovered the 1–5 (0.35±0.03; 95%CI: 0.29–0.41;
𝑃 = 0.000116 versus PSL) and 2–4 (0.98±0.04; 95%CI: 0.90–
1.06; 𝑃 = 0.000131 versus PSL) toes distances, to the levels of
sham operated rats (Figure 6).
3.6. GABA-B Ligands Reduce the Nerve Inflammatory Cells.
We evaluated the recruitment of activated macrophages,
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Figure 6: Assessment of locomotor coordination and gait analysis after GABA-B ligands treatment. (a) Histograms of the analysis of the
distance between toes 1–5. (b) Histograms of the analysis of the distance between toes 2–4. Data are expressed as mean ± SEM. Statistic with
one-way Anova and Tuckey’s post hoc test. ∗∗∗
𝑃
< 0.001.
assessing the immunopositivity for CD68 as an index of
nerve inflammation.The transverse sections of sciatic nerves
showed the typical normal myelin structure, evidenced in
red with FluoromyelinTM staining, in sham and CGP56433
treated rats (Figure 7). As expected, the myelin rings were
altered in PSL and baclofen treated animals, confirming the
morphologic results.The absence of CD68 immunopositivity
excluded any macrophage infiltrate in sham operated ani-
mals. By contrast, in PSL and in PSL plus baclofen rats sev-
eral macrophages infiltrated the nerve, indicating a general
increase in neuroinflammation (CD68 in green). In partic-
ular the merged images (in yellow) revealed a CD68 posi-
tivity in the cells infiltrating the myelin structure (Figure 7).
Indeed, the infiltrated macrophages totally disappeared after
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treatment with CGP56433 or with baclofen plus CGP56433
(Figure 7), demonstrating that only the antagonist CGP56433
proved able to counteract themacrophagic recruitment in the
nerve, regardless of the presence of baclofen.
4. Discussion
The identification of new treatments for nerve regeneration
and chronic neuropathic pain is currently a challenge for
clinical neurologists. Improvements in therapy rely on the
complete comprehension of the mechanism inducing these
pathologies.This will contribute to change the future therapy
of pain from a symptomatic towards a molecular approach.
By using the PSLmodel of nerve injury, we observed the onset
of tactile hypersensitivity (i.e., allodynia) beside an alteration
of the nerve morphology and myelin proteins expression.
PSL is an experimental model that mimics the complex
regional pain syndrome named CRPS-II, including the com-
plex combination of rapid onset allodynia and hyperalgesia
[1, 2]. However, the morphological features of injured nerves
and the expressions of the two most important peripheral
myelin proteins, P0 and PMP22 [53], were poorly inves-
tigated. We observed a severe degeneration in the nerve
structure with loss of large myelinated fibers, nerve demyeli-
nation, and phagocytosis. The P0 and PMP22 expression
was strongly decreased, confirming a massive degenerative
process affecting the Schwann cells-myelin forming compart-
ment of the peripheral nerves. According to the literature
[52], we expected that the nerve degeneration would be equal
for axons of all sizes and may affect either the myelinated
(type Abeta/Adelta) or the unmyelinated (type C, mostly
nociceptors) fibers.
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Additionally, we evaluated the putative therapeutic effects
of two GABA-B ligands on the altered behavioural, bio-
chemical, and morphological parameters of the PSL model.
The choice to use baclofen, as a GABA-B ligand, relies
on our previous findings demonstrating the involvement of
GABA-B receptors in PNS. GABA-B receptor is important
for the control of Schwann cell biology, for the process of
myelination and for the peripheral nociception [36, 37, 55,
56]. Despite the role of GABAergic system in neuropathic
pain, however, GABA-B receptor agonists are rarely used
in clinic to treat neuropathic pain mainly because of their
narrow therapeutic window. Baclofen showed antiallodynic
and antinociceptive actions in chronic pain models in rats,
such as the PSL [57, 58]. Baclofen was also used in a limited
number of clinical trials to treat some types of neuropathic
pain, including the use of spinally administered baclofen to
enhance the spinal stimulation effects [39, 42, 59]. However,
its use was limited because of its sedative properties and the
rapid development of tolerance. Indeed, CGP56433 is a high-
affinity antagonist of GABA-B receptor, active at nanomolar
concentration in numerous in vitro and in vivo studies [60,
61]. CGP56433 was not previously used for regenerative
purposes of the PNS, so that our results are the first to
determine the potentiality of GABA-B ligands for peripheral
nerve repair and for the concomitant control of neuropathic
pain.
Surprisingly, in our studies the agonist baclofen and the
antagonist CGP56433 exerted a synergic effect. This additive
phenomenon in the nervous system is not common, although
aGABA-B ligand synergic effect on brain stimulation rewards
was described [62]. The GABA-B agonist CGP44532 and
the antagonist CGP56433 induced a reward decrement
when administered separately, while their coadministration
induced an additive effect on threshold, rather than blocking
the agonist-induced threshold elevations [62]. However, part
of the effects achieved with CGP56433 treatment alone (for
instance the nociceptive responses, the number ofmyelinated
fibers, and the gait) may result from the blocking of GABA-B
receptor activation by endogenous GABA.This is compatible
with the capacity of peripheral nerves (i.e., the Schwann cells)
to synthesize and release GABA [63]. Schwann cells, indeed,
resulted to be particularly responsive to CGP56433, revealing
a specific effect mediated by the GABA-B receptors present
on their cell surfaces. Baclofen decreases the proliferation
and the myelin proteins expression in Schwann cells [36]. As
expected, the GABA-B antagonist significantly upregulated
the levels of the myelin proteins P0 and PMP22.
Considering the possible involvement of Schwann cells
in neuropathic pain [64], our findings suggest that the
synergic effects exerted by baclofen plus CGP56433 may be
the result of a double simultaneous action of CGP56433,
through the myelin-forming component and by baclofen,
likely through the neuronal (central and/or peripheral) com-
partment. Indeed, given the synergic effects on locomotors
activities, the activation of mixed central and peripheral
targets by those molecules should not be excluded. However,
very recent findings supported the hypothesis that GABA-B
receptors may also control the nonmyelinating Schwann cells
committed to ensheath the nociceptive fibers, strengthening
a GABA-B role in the regulation of Schwann cell fate and
nociceptive pathways in the PNS [37, 38].
PSL induces early signs of damage of the motor com-
partment. They include loss of normal spread between toes
(e.g., 1–5 and 2–4 toes), loss of ventroflexion of toes, and
consequent increase of length print [65]. Our gait analysis is
in agreement with these events, confirming a PSL-induced
damage of the nerve peripheral motor compartment and
a CGP56433/baclofen significant recovery to normal gait.
Interestingly, CGP56433 alone partially recovered the 1–5
and 2–4 toes distances, suggesting that these effects may be
ascribed to the antagonism of the GABA-B mediated tonic
control of motor coordination.
In the PNS, macrophages are committed to neuroim-
mune surveillance and they intervene during the Wallerian
degeneration following axonal injury [66]. Macrophages
concur to the onset of pain hyperactivity; thus a decrease
in their recruitment is a desirable process [64]. The lack
of their recruitment that we observed following CGP56433
and CGP56433-baclofen treatments is in agreement with a
protection against neuroimmune-induced neuropathic pain,
revealing that only the GABA-B antagonist is active. This
is not surprising, since GABA-B receptors were found in
macrophages [67].
Although we believe that most of the effects observed are
due to a direct action of drugs on peripheral components, the
involvement of central pathways should not be excluded. It is
indeed reported that central mechanisms of GABA ligands,
administered intrathecally, equally affect the behavioural
signs of neuropathy [46, 68]. Therefore, the role of GABAer-
gic system in pain appears to be quite complicated, since the
transmitter may have both pro- and antinociceptive effects
[69–71], and the route of administration may discriminate in
this sense. The possibility to administer GABA-B ligands in
situ by a drug delivery system, close to the nerve injury site,
is an important issue to minimize the central effects, which
deserves further investigations.
5. Conclusions
In this paper we tried to shed light on the molecular
mechanisms associating GABA-B receptors, nerve degener-
ation/regeneration, and peripheral nociception. We hypoth-
esised that GABA-B mediated effects arise from direct and
indirect effect on the axonal and Schwann cell compartments,
respectively. Although an activation of mixed central and
peripheral effects should not be excluded, our results suggest
that the simultaneous treatmentwith baclofen andGCP56433
exerts a peripheral synergic effect in promoting nerve regen-
eration after injury and likely ameliorates the neuropathic
pain.
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